Showing results (201-210 of 336) with videos related to

Sort By:
Pageof 34
Medizinische Klinik (Munich, Germany : 1983)|February 15, 1996
[Cytokine therapy and the endocrine system: is it necessary to monitor more than the thyroid gland?]F Schuppert, E Müller-Kunert, W Stöcker, et al.
Anticancer Research|September 1, 1993
Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapyA V Timoshenko, K Kayser, P Drings, et al.
World Journal of Urology|June 21, 2002
Recent strategies for the use of paclitaxel in the treatment of urological malignanciesC Bokemeyer, J T Hartmann, M A Kuczyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancerC Bokemeyer, A Gerl, P Schöffski, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|January 9, 2004
[Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]A C Pfannenberg, K Oechsle, C Kollmannsberger, et al.
BMC Cancer|November 10, 2016
Improved nutrition in adolescents and young adults after childhood cancer - INAYA studyJ Quidde, J von Grundherr, B Koch, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 1, 1997
[An interdisciplinary consensus conference on the diagnosis and therapy of testicular tumors]M Bamberg, H J Schmoll, L Weissbach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumorsC Bokemeyer, O Köhrmann, J Tischler, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumoursC Schöber, E Schmoll, H J Schmoll, et al.
Pageof 34